Clinical study for the efficacy and safety of multi-target regimen in the treatment of relapsed/refractory T-cell acute lymphocytic leukemia.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035164

Enrollment

Unknown

Registered

2020-08-02

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory T-cell acute lymphocytic leukemia,RR-T-ALL

Interventions

trial group:multi-target chemotherapy

Eligibility

Sex/Gender

All

Age

14 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Relapsed /refractory T-cell acute lymphocytic leukemia, RR-T-ALL; 2) Patients signing informed consent must be able to understand and willing to participate in this study, and sign informed consent at the same time.

Exclusion criteria

Exclusion criteria: 1) Exclude pregnant, preparing for pregnancy or lactating women; 2) Exclude patients with myelodysplastic syndrome (MDS), chronic myeloproliferative disease (MPN) and lymphoproliferative disease; 3) Exclude patients with severe liver and kidney and other important organ dysfunction or diseases affecting the treatment prognosis; 4) Exclude patients with other diseases that cannot be controlled and may limit patients' participation in this trial; 5) Exclude any circumstances that the investigator thinks are not suitable for the participants and that may increase the risk of the subjects or interfere with the test results.

Design outcomes

Primary

Measure	Time frame
CR;ORR;PR;MRD;Fusion gene quantification of BCR-ABL;OS;EFS;safety;	—

Countries

China

Contacts

Public ContactLi Hui

Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital

lihui606606@163.com+86 18981838256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026